Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Doug Shapiro who wrote (3168)	3/29/1998 11:05:00 PM
From: Bruce Rosen	Read Replies (1) \| Respond to of 7041

This thread has had numerous links posted to information about tests of phentolamine going back decades as well as links to Zonagen's SEC filings, including the prospectus for its secondary offering last July. You can see those by going to www.edgar.com and typing in ZONA.. I would encourage you to call the company and request a copy of the report called a "white paper" that the company put out a few months ago. It gave a nice overview of the Vasomax story. I have seen efficacy ranges from 35% to 62%, depending on how thorough a job was done in screening out placebo responses. The Phase III tests showed strong statistical significance. << This will not do it for the FDA they need evidence of effectiveness greater than this to approve this drug for oral use considering that they now have one approved with a very nice safety profile, unless oral phentolamine has a better safety profile than Viagra which I doubt. >> From what I can see, less information has been released about Viagra than Vasomax. I did see one observer's report that said the side effect profile on Viagra was worse than for Vasomax. Do you think the FDA will take into account the different mechanisms of action for the two drugs?